TY - JOUR
T1 - Therapeutic myocardial angiogenesis
T2 - Past, present and future
AU - Scheinowitz, Mickey
N1 - Funding Information:
The author thanks Prof. I. Binderman for careful reviewing the manuscript. The study was partially supported by grants from Tel-Aviv University and Israel Ministry of Health.
PY - 2004/9
Y1 - 2004/9
N2 - One of the main goals in the treatment of myocardial ischemia is the development of effective therapy for angiogenesis and neovascularization. The first evidence demonstrating alleviation of myocardial ischemia and increased number of collateral blood vessels was reported in the early 90s following intra-coronary administration of basic fibroblast growth factor protein in canine. This study established the ground for extensive investigations to demonstrate the use of other angiogenic growth factor proteins, genes administered directly or incorporated in viruses, and more recently, endothelial progenitor stem cells (embryonic and adults). The positive results observed in animals failed, in most cases, to repeat themselves in clinical trials in human patients. Therefore, additional experiments are warranted to allow full understanding of the mechanism underlying new blood vessel formation before further clinical studies are undertaken. This review will explore the milestones of angiogenic investigations and their clinical application.
AB - One of the main goals in the treatment of myocardial ischemia is the development of effective therapy for angiogenesis and neovascularization. The first evidence demonstrating alleviation of myocardial ischemia and increased number of collateral blood vessels was reported in the early 90s following intra-coronary administration of basic fibroblast growth factor protein in canine. This study established the ground for extensive investigations to demonstrate the use of other angiogenic growth factor proteins, genes administered directly or incorporated in viruses, and more recently, endothelial progenitor stem cells (embryonic and adults). The positive results observed in animals failed, in most cases, to repeat themselves in clinical trials in human patients. Therefore, additional experiments are warranted to allow full understanding of the mechanism underlying new blood vessel formation before further clinical studies are undertaken. This review will explore the milestones of angiogenic investigations and their clinical application.
KW - Angiogenic growth factors
KW - Bone marrow
KW - Embryonic stem cells
KW - Endothelial progenitor cells
KW - Hematopoietic stem cells
KW - Umbilical cord blood
UR - http://www.scopus.com/inward/record.url?scp=5544319198&partnerID=8YFLogxK
U2 - 10.1023/B:MCBI.0000044376.78158.51
DO - 10.1023/B:MCBI.0000044376.78158.51
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:5544319198
SN - 0300-8177
VL - 264
SP - 75
EP - 83
JO - Molecular and Cellular Biochemistry
JF - Molecular and Cellular Biochemistry
IS - 1-2
ER -